However, the requirement for β cell CCK in obesity-driven PDAC has not yet been firmly established in preclinical models and competitive CCK receptor antagonists may not be potent enough to counter the presumably high local concentrations of obesity-induced CCK within the pancreas (Chung et al, 2020). The gene discussed is CCK; the disease is obesity disorder.